MedElevator Войти в исследования
← Поиск публикаций

DOI 10.64898/2026.06.26.26356369

Медицинская библиотека · medRxiv : the preprint server for health sciences · 2026

Statins May Not be Associated with a Reduction in Primary Cardiovascular Events in Patients with Systemic Lupus Erythematosus.

Goren Lea R, Petri Michelle, Fava Andrea, Goldman Daniel, Magder Laurence, Adamo Luigi

СтатьяПрепринтПеревод в очереди

Аннотация

IMPORTANCE

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in patients with Systemic Lupus Erythematosus (SLE), due to both traditional CVD risk factors and SLE specific factors. Although statins are first-line therapy for primary prevention of CVD in the general population, it is unclear whether statins protect against first time cardiovascular events (CVEs) in patients with SLE.

OBJECTIVE

Determine whether statins are protective in primary prevention of CVEs among patients with SLE.

DESIGN SETTING AND

PARTICIPANTS

This cohort study is a retrospective analysis of a well-characterized, prospective cohort of patients with SLE with patient follow-up beginning in 2013.

MAIN OUTCOME AND MEASURES: CVEs were defined as the occurrence of myocardial infarction, thrombotic stroke, onset of angina, or coronary bypass procedure. Statin use in the prior year was quantified based on standardized defined daily doses (DDD). Rates of occurrence were compared using pooled logistic regression. A multivariable model was performed to adjust for possible confounders.

RESULTS

The analysis was based on 8708 person-years of follow-up from 1396 cohort participants: 1283 (92%) were women, 567 (41%) Black, and 665 (48%) White. Patients were stratified by use of statin within the last year: none, < standard DDD, or ≥ standard DDD. The rate of events per 1000 person-years was respectively 5.3, 8.5, and 8.0 (p=0.31) within these 3 groups, suggesting potential lack of protective effect of statin treatment. The rates of CVEs among statin versus non-statin users remained the same after adjusting for and stratifying by total cholesterol level (p=0.18). Significantly higher rates of CVEs occurred among those with BMI 25-30 kg/m 2 (p=0.0066) and those prescribed ≥ 10 mg/day of prednisone (p=0.0003). Multivariable analysis also suggested a potential lack of protective effect of statins against CVEs (OR 1.48; 95% CI, 0.79-2.75; p=0.21883) and diabetes mellitus was found to be independently associated with an increased risk for development of CVEs (OR 4.48; 95% CI 1.99-10.08; p=0.00029).

CONCLUSION AND RELEVANCE: Among patients with SLE, statin use may not be protective in primary prevention of CVEs, regardless of statin exposure. Prednisone use, history of diabetes mellitus, and elevated BMI were drivers of increased cardiovascular risk in univariate analysis. Diabetes mellitus persisted as an independent risk factor for CVEs in a multivariable model. Our work reinforces findings from clinical trials which have shown no reduction in subclinical measures of atherosclerosis with statin use among patients with SLE, as well as a mechanistic substudy which demonstrated that statins are ineffective in normalizing the pro-atherogenic changes induced by SLE.

Для цитирования: Goren Lea R, Petri Michelle, Fava Andrea, Goldman Daniel, Magder Laurence, Adamo Luigi. Statins May Not be Associated with a Reduction in Primary Cardiovascular Events in Patients with Systemic Lupus Erythematosus.. medRxiv : the preprint server for health sciences. 2026. DOI: 10.64898/2026.06.26.26356369.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.